News

Loading...

Roche HIV Global Access Program expands to include next-generation automated platform solutions

High throughput cobas® systems help optimize workflow for resource-limited settings Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced the expansion…

Explore

Roche Receives FDA Approval for Use of SurePath Preservative Fluid with cobas HPV Test for Cervical Cancer Screening

Roche HPV test is first to be approved for use with the SurePath Preservative Fluid gynecologic cell collection…

Explore

Roche announces availability of the LightMix Modular Zika Virus Assay (CE) in markets accepting the CE mark

Roche (SIX: RO, ROG; OTCQX: RHHBY) and TIB MOLBIOL, GmbH, announced today the availability of the LightMix Modular Zika Virus…

Explore

FDA Grants First Liquid Biopsy Approval to the Roche cobas® EGFR Mutation Test v2

Test can be used with either plasma or tumor tissue, as a companion diagnostic for non-small cell lung cancer therapy.

Explore

Roche announces the first FDA-approved CMV test for use in hematopoietic stem cell transplant recipients

New test standardizes CMV testing for both solid organ and hematopoietic stem cell transplant recipients.

Explore

Roche receives approval in Japan for the cobas® EGFR Mutation Test v2 

New test includes expanded mutation coverage to detect EGFR mutations in non-small cell lung cancer patients.

Explore

New Roche HBV Test expands cobas® 4800 System menu 

Complete virology portfolio strengthens high medical value capabilities

Explore

Roche receives FDA approval for HIV-1 viral load test on the cobas® 6800/8800 Systems

HIV-1 test expands menu for highly automated molecular platforms that offer fastest time to results.

Explore
Loading...